Pemlimogene merolisbac (Aduro Biotech/Jannsen Biotech)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NamePemlimogene merolisbac (Aduro Biotech/Jannsen Biotech)
Drug Alias NameADU-214JNJ-64041757
ClassificationVaccines > Development/production technology > Live attenuated vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungAdenocarcinoma of Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAduro Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJanssen Research & Development Llc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungAdenocarcinoma of Lung

Other Information

ATC CodeN/A
Related LinksN/A